MET and neoplasm: We observed that patients with tumor samples showing strong (score 3+) c-MET IHC staining had a shorter mOS than those with weak or moderate (score 1+ ~ 2+) c-MET IHC staining (5.7 vs. 24.8 months, p = 0.013; Figure 2B).